Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07386678
Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment
Disease or general study area: Uncomplicated rhegmatogenous retinal detachment (RRD) and risk of proliferative vittroretinopathy (PVR) Purpose and nature of the study: 1. Characterise the cytokine profile of vitreous fluid in uncomplicated RRD. 2. Develop a risk model to predict development of PVR after retinal detachment surgery using imaging and molecular biomarkers. 3. To develop deep learning/artificial intelligence (AI) models for PVR detection in retinal detachment. Inclusion criteria: 50 adult ( ≥18 years) patients with uncomplicated rhegmatogenous retinal detachments without PVR. What participating will involve: Pre- and post-operative assessments and intervention will follow standard of care for patients with rhegmatogenous retinal detachments. Additional intervention will include non-invasive imaging of anterior chamber flare, vitreous, wide-field retina, macula optical coherence tomography (OCT) and macula OCT-angiography (OCT-A) as well as, seeking participant's consent on collecting their vitreous fluid at time of their surgery for cytokine analysis.
Gender: All
Ages: 18 Years - Any
Updated: 2026-02-10
NCT05523869
Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy
Intravitreal topotecan has anti-inflammatory, anti-proliferative and anti-fibrotic activity that we hypothesize may exhibit high efficacy for the treatment of proliferative vitreoretinopathy (PVR) in patients with rhegmatogenous retinal detachment (RRD). A high efficacy for intravitreal topotecan has been exhibited in cell cultures of PVR. At the same time, intravitreal topotecan has been routinely used in the treatment of vitreous seeds from retinoblastoma. At doses of 5-30 micrograms per injection, no adverse events have been reported with the use of intravitreal topotecan. Therefore, the current prospective matched phase II trial aims to investigate the efficacy and safety of intravitreal topotecan for severe PVR in patients with RRD.
Gender: All
Ages: 18 Years - Any
Updated: 2025-02-11
1 state